Sigma-tau Industrie Farmaceutiche Riunite, Research and Development, Pomezia, Italy.
Med Mycol. 2012 Apr;50(3):225-33. doi: 10.3109/13693786.2011.648215. Epub 2012 Feb 7.
Infection caused by Aspergillus fumigatus remains a major therapeutic challenge in immunocompromised individuals. Innate immunity represents the first line of defense against pathogens. In the last 20 years, several proteins belonging to this arm of the immune system have been characterized as being endowed with antifungal activity. Among these, the prototype long pentraxin PTX3 has been identified as a non-redundant protective factor against infections caused by A. fumigatus. A number of relevant animal models of invasive aspergillosis have indicated that PTX3 exerts its protective activity in several conditions of immunosuppression. In this article, we review the current understanding of PTX3 mechanisms of action that might be of help in further exploration of the pharmacological activity of this protein against A. fumigatus.
烟曲霉感染仍然是免疫功能低下个体的主要治疗挑战。先天免疫是抵御病原体的第一道防线。在过去的 20 年中,已经有几种属于免疫系统这一部分的蛋白质被鉴定为具有抗真菌活性。其中,原型长 pentraxin PTX3 已被确定为对抗烟曲霉感染的非冗余保护因子。一些相关的侵袭性曲霉病动物模型表明,PTX3 在几种免疫抑制情况下发挥其保护作用。在本文中,我们回顾了 PTX3 作用机制的最新认识,这可能有助于进一步探索这种蛋白质对烟曲霉的药理活性。